HealthCap’s Post

🫀💵Great new day for the team at CorFlow as they announce €44M in new #funding toward their novel, CoFl, diagnostic and drug delivery platform for #microvascular obstruction (MVO). CorFlow’s CoFI system provides physicians with the ability to both detect and delivery therapy to life threatening MVOs in patients suffering acute #coronary events while still in the cath lab. The Series B will fund CorFlow’s MOCA II (MVO with CoFI System Assessment II) pivotal study across the US and Europe validating efficacy to diagnosis MVOs in heart attack patients post stent implementation as well as study for their adaptive therapeutic delivery platform. This latest round was co-led by Broadview Ventures Inc and Panakes Partners alongside 415 Capital, CorFlow’s initial VC investor and largest shareholder. "CorFlow’s breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible. We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.” - Barbara Castellano, Partner at Panakes Partners #medtechmoney #coronarydisease #venturecapital #medicalinnovation The Mullings Group

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity to Grow Your HSA with Fortress Biotech's Recent FDA Approval and Upcoming PDUFA Date! 💪💼🚀 Fortress Biotech, Inc. has recently made significant strides in the healthcare sector, capturing the attention of investors seeking to make the most of their Health Savings Accounts \(HSA\). The company announced that its revolutionary product, Emrosi, designed to treat inflammatory lesions of rosacea in adults, has received FDA approval on November 4, 2024. This approval is a significant milestone for Fortress Biotech, signaling its commitment to delivering innovative solutions that enhance wellness and improve the quality of life for patients suffering from this common skin condition. In addition to the FDA approval for Emrosi, Fortress Biotech has also disclosed an upcoming PDUFA date for cosibelimab, further bolstering investor enthusiasm. Cosibelimab is anticipated to bring new opportunities in the immunotherapy field, potentially revolutionizing treatment options for various medical conditions. While Fortress Biotech's financial results have shown a net loss, it is important to remember that investing in the healthcare industry is a long-term game. By capitalizing on burgeoning healthcare advancements, you have the power to not only grow your HSA but also support breakthrough innovations that can positively impact the lives of countless individuals. Don't let the Fear of Missing Out \(FOMO\) hold you back! Act now and explore the potential of investing in Fortress Biotech, leveraging the growth prospects offered by Emrosi's FDA approval and the upcoming PDUFA date for cosibelimab. Let your HSA flourish by investing in the future of healthcare. #hsa #investing #healthcare #health #family #wellness 📈💰💼💪❤️🏥

Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight loss in a Phase IIa study. #GLP1 #obesity #biospace https://hubs.li/Q032fKqc0

💡 𝐁𝐢𝐠 𝐍𝐞𝐰𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐒𝐩𝐚𝐜𝐞! 💡 Immedica Pharma AB has announced its agreement to acquire Marinus Pharma, marking a transformative milestone in the fight against rare seizure disorders. This acquisition brings ZTALMY® (ganaxolone) oral suspension, an FDA-approved breakthrough for treating CDKL5 deficiency disorder (CDD) seizures, to Immedica's portfolio. This move expands Immedica's rare disease focus into North America and strengthens its mission to deliver life-changing treatments for underserved patients. 💬 What does this mean for patients? More access to innovative therapies and hope for improved outcomes. 👉 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐢𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐡𝐞𝐫𝐞: https://lnkd.in/gdY7HyFm #rarediseases #pharmainnovation #seizuredisorders #pharmaceuticalnews #healthcareinnovation #immedicapharma #marinuspharma #medicalbreakthroughs #fdaapproved #rarediseasetreatment #globalhealth #healthcareleadership

Synairgen plc (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk patients with severe viral lung infections who are on ventilation. "Having closely analysed various routes forward, we are confident that our focus on these high-risk patients is optimal from both a clinical and commercial perspective," said CEO Richard Marsden. Researchers have now designed the study and worked to optimise aerosol delivery of SNG001 into ventilator circuits. Management, meanwhile, has held discussions with a specialised clinical research group to support the planned clinical evaluation. Marsden told investors: "To initiate this sizeable trial, additional funding will be required, and we will keep investors updated on plans as they finalise." More at #Proactive #ProactiveInvestors http://ow.ly/lFYt105JWnI

Zevra Therapeutics are sponsoring The Ehlers-Danlos Society this vEDS Action Month! ⁠ "Vascular Ehlers-Danlos syndrome (vEDS) is a life-threatening #raredisease, which is why Zevra Therapeutics is committed to bringing a new treatment to the #vEDS community. "Through our Decentralized Study Evaluating Celiprolol on VEDS Related Events (DiSCOVER) clinical trial, we are investigating celiprolol as a potential therapy for VEDS. Want to know if you’re eligible? Learn more about our DiSCOVER trial and enroll here." https://lnkd.in/efSZrnZB #Sponsored #SponsoredPost #Ad #ClinicalResearch #RareDisease #VEDS #VascularEhlersDanlosSyndrome #VascularEDS #EDS #EhlersDanlosSyndrome #VEDSActionMonth #ClinicalTrial

On Monday, Bridgewater-based Bausch + Lomb announced that its affiliate had acquired Whitecap Biosciences. Whitecap Biosciences is developing two innovative therapies for potential use in glaucoma and geographic atrophy. The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline.

“We punch well above our weight,” says Jeremy Sturgess-Smith, the co-founder and finance director of Aquis-listed Ananda Developments Plc (AQSE:ANA) whose CBD-derived lead asset, MRX1, is showing promise in chronic pain and heart disease. With a valuation of just under £16 million, you would also say Ananda has flown well below the radar given the phase II-ready status of MRX1 and pre-clinical data shared with the market last week. A Nasdaq-listed company with those credentials might expect to have an additional nought on the end of that figure above (at the least). But this is the hard reality of UK life science at the moment – drug development groups of Ananda’s ilk just don’t receive the recognition or funding of their American counterparts. It has led to a handful of small innovators, including Redx Pharma and C4X Discovery, to quit the public arena.  Badge of honour That’s not something Ananda is... More at #Proactive #ProactiveInvestors http://ow.ly/FnG5105zpX1

**Only put off until tomorrow what you are willing to die having left undone** **Oruka Therapeutics Reports Successful Go-Public Transaction and Progress on Clinical Programs with Over $475 Million Raised in 2024** 🔥📈 Don't Miss Out on Investing in the Future of Healthcare! Act Now! 💪💰 Quiver AI Summary: Oruka Therapeutics, Inc. has recently completed a triumphant go-public transaction, raising an impressive $475 million in 2024. This substantial funding provides the company with the financial resources to propel its clinical programs forward. With a focus on developing treatments for chronic skin diseases, Oruka Therapeutics aims to revolutionize healthcare and improve the lives of countless patients. This exhilarating development presents an incredible investment opportunity within the Health Savings Account (HSA) realm. By investing in Oruka Therapeutics, individuals can not only potentially grow their HSA funds but also contribute to advancing critical medical solutions. As an experienced Investment Advisor, I urge you to seize this chance to be a part of the future of healthcare. #hsa #investing #healthcare #health #family #wellness 💼💰🏥💪👨👩👧👦❤️💪🌟 Invest Now and Experience the Thrill of Empowering Healthcare Advancements! Contact me for personalized guidance and start building a brighter future for your HSA investments.

$MRK announces that its pivotal Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept) met the primary endpoint at the interim analysis, marking a significant step forward in treatment development: https://ibn.fm/i5a1m #Merck #ZENITHTrial #WINREVAIR #Sotatercept